Germany's Heilmittelwerbegesetz (HWG) limits how treatments may be advertised to the public: it restricts testimonials and case histories, bans before/after images for cosmetic surgery, and bans prescription-medicine advertising. Doctors are also bound by their Landesärztekammer's professional code, and competitors and associations enforce all of it through warning letters.
This is a working summary for marketing teams, not legal advice. Every rule below names the instrument it comes from so you can read the source rather than take our word for it, and so you can tell when something here has gone out of date.
Who regulates healthcare advertising in Germany
- Heilmittelwerbegesetz (HWG): §3 misleading advertising, §7 gifts, §9 remote treatment, §10 prescription medicines, §11 banned forms of public advertising, §15 fines
- Gesetz gegen den unlauteren Wettbewerb (UWG), including the fake-review rules added in 2022
- (Muster-)Berufsordnung für Ärzte (MBO-Ä) §27, binding through each Landesärztekammer's own Berufsordnung
- GDPR (DSGVO) Art. 9, the BDSG and professional secrecy under §203 StGB
More than one of these usually applies at once. A campaign can satisfy the advertising regulator and still breach the data-protection one, which is the failure mode that catches most practices: the creative gets reviewed and the tracking does not.
The rules that actually change what you can publish
- Testimonials are restricted, not generally permitted. HWG §11(1) bars third-party letters of thanks, recognition or recommendation, and reproduced case histories, where they are used in an abusive, repulsive or misleading way. Recommendations by scientists, health professionals or celebrities may not be used to advertise medicines to the public.
- Before/after images are banned for operative plastic-surgical procedures, and so is advertising for those procedures aimed mainly at children and adolescents (HWG §11(1)). Non-surgical treatments fall under the misleading-advertising rules.
- No misleading efficacy claims or promised results (HWG §3; UWG §5). Doctors may not advertise in a laudatory, misleading or comparative way (MBO-Ä §27(3)).
- Prescription-only medicines may not be advertised to the public (HWG §10), which keeps botulinum toxin brands out of consumer ads.
- Online reviews are restricted too: fake or unverified reviews are blacklisted under the UWG, and replies must not confirm that someone was a patient (§203 StGB).
- Gifts and other inducements are limited (HWG §7), and doctors' fees must follow the GOÄ or GOZ fee schedule.
- Sponsored and influencer posts must be labelled as advertising (UWG §5a).
- There is no pre-approval. Enforcement comes after publication through warning letters (Abmahnung) and injunctions, and HWG fines reach €50,000 (HWG §15).
How Branding Pioneers handles it
- German-language copy with an Impressum, evidence on file for every claim, and no “beste”, “garantiert” or “schmerzfrei”.
- No before/after images for plastic surgery and no prescription-medicine or Botox brand names.
- No paid or solicited testimonials, and no review gating or incentives.
- The treating clinician signs off every asset, and German medical-law counsel reviews each new campaign type.
- Explicit GDPR Art. 9 consent for patient images, EU hosting, and standard contractual clauses before anyone in India can access data.
- Flat retainer or fixed project fee, never per patient or per lead.
Tracking deserves the same scrutiny as copy. Analytics, pixels and remarketing tags routinely collect more than a healthcare provider is permitted to share, and the default installation of most of them is not compliant in Germany. Audit what your tags send before you audit your ad copy.
Before you run anything
- Can you substantiate every claim in the creative, today, from a document you can produce?
- Do you have written consent for every patient who appears, covering this specific use?
- Has the approval or licence this market requires been granted, and is its number on the creative where required?
- Does your tracking send anything that identifies a patient or their condition?
- Has someone qualified in Germany reviewed the campaign, not just the marketing team?
If the answer to the last one is no, that is the gap worth closing first. We work inside these rules daily and will tell you when something you want to publish is not worth the exposure, but we are a marketing agency, and a regulated market deserves a qualified reviewer as well.
Not legal advice. A planning summary of published rules, last checked on 11 October 2026. Rules change, so confirm the current text with the regulator or local counsel before relying on it.
